Generex v. TheStreet.com [1]

On April 6, 2010, Generex, a biotechnology company, filed a lawsuit in state court against TheStreet.com, a financial news website, and Adam Feuerstein, a senior columnist, for statements published on the website's Biotech Stock Mailbag about the company.

Generex has been in the process of developing and seeking regulatory approval for Oral-Lyn, an insulin spray treatment for Type-1 and Type-2 diabetes. In two posts published on March 19, 2010 and March 26, 2010, Mr. Feuerstein wrote that "none of the Oral-Lyn data collected by Generex has been peer-reviewed by credible medical journals" and that "the company is using science and the quest to develop an alternative insulin delivery method not to actually help diabetics but as a ruse to perpetuate a 15 year-long stock promotion scheme."

In the complaint, Generex claims that these statements constitute libel, libel per se, product disparagement, and injurious falsehood, and is seeking $250,000,000 in damages.